Amtagvi Becomes the First Approved T-Cell Therapy in Solid Tumors
On Friday, February 16, Iovance Biotherapeutics announced (press release) that the FDA granted accelerated approval to Amtagvi (lifileucel), a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy to treat adult patients with unresectable or metastatic melanoma after anti-PD1 and targeted therapy. Below, Celltelligence provides insights on the importance of Amtagvi’s approval in the solid tumors field, while discussing Iovance’s plans and pipeline.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.